GlassScriptPhysician profile
Louis J Rivello
NPI 1598754848
$183.91
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $41.55.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $50.33 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $19.37 | 2019 | |
| Celgene Corporation | $19.34 | 2019 | |
| Tesaro, INC. | $17.27 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $15.33 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13.08 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.77 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.32 | 2019 | |
| Emd Serono, INC. | $12.09 | 2020 | |
| Dova Pharmaceuticals | $12.01 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis Rivello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.